Media

Home

Media

News Releases

NEWS RELEASES

13

GemVax Secures Orphan Medicinal Product Designation in Europe, Following Approvals in the United States and Republic of Korea
2025-05-29
12

GemVax’s GV1001 Receives FDA Fast Track Designation for Progressive Supranuclear Palsy Treatment
2025-05-07
11

GemVax Receives Orphan Drug Designation from U.S. FDA for Progressive Supranuclear Palsy Treatment
2025-05-02
10

Seoul National University Bundang Hospital Establishes the first “International PSP Research and Treatment Center” in Korea
2024-12-09
9

GemVax Presents Poster on Topline Results of PSP Phase 2a Trial at International Conference
2024-11-26
8

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
2024-10-29
7

GemVax's GV1001 Reduces Alzheimer’s Amyloid Beta to Normal Levels
2024-09-30
6

GemVax & KAEL Co., Ltd. Confirms Participation as Signature Sponsor at Neuro2024
2024-09-25
5

GemVax Confirms Potential for Preventing Alzheimer's Disease in Periodontitis Patients with GV1001
2024-06-05
4

GemVax Completes Global Phase 2 Patient Recruitment for Alzheimer’s Disease Drug
2024-04-12
3

GemVax Completes Phase 2 Patient Recruitment for Progressive Supranuclear Palsy Trial
2024-03-28
2

GV1001, GemVax's Progressive Supranuclear Palsy Treatment, Designated as Orphan Drug by Ministry of Food and Drug Safety
2024-02-23
1

GemVax Receives FDA Phase 2 IND Approval for 'GV1001' in the Treatment of Progressive Supranuclear Palsy
2024-02-13

게시물 검색